NBP

0.83005.66%
MH

Mark Hagler

President & Chief Commercial Officer

Mr. Mark Hagler is President & Chief Commercial Officer of NovaBridge Biosciences from April 22, 2026. He is a biotechnology commercial executive with many years of experience building, scaling and transforming biopharmaceutical and specialty pharmaceutical businesses. He brings distinctive expertise in driving accelerated growth, commercial readiness and organizational development for companies in oncology, immunology, ophthalmology and rare disease markets. Before joining NovaBridge, he served as Chief Commercial Officer for Sun Pharmaceuticals Industries Limited, where he led a 1B+ portfolio and organization of 600+ professionals, with accountability for strategy, performance and growth. Under his leadership, Sun’s U.S. Oncology business scaled from inception to profitability. He led the transformation of the Ophthalmology division, establishing robust operational standards and delivering positive cash flow. He executed strategic acquisitions that added value to the company’s pipeline and expanded its market reach. Earlier in his career, he held senior leadership roles at Ipsen S.A., Sanofi, Novartis AG and Abraxis BioScience Inc., where he shaped the global launch and lifecycle strategies for oncology therapies including Afinitor® and Abraxane®, driving meaningful clinical adoption and long-term commercial value. His experience spans IND-to-commercialization drug development, pipeline prioritization, business development, pricing and market access strategy, cross-functional organizational leadership and field model optimization for high-science markets. He is a named inventor on three U.S. design patents for medical technology innovations. He holds an MBA in Corporate Finance from Johns Hopkins University and is a graduate of the United States Naval Academy.

Positions